↓ Skip to main content

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers

Overview of attention for article published in Cancer Chemotherapy & Pharmacology, May 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 1,934)
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
twitter
1 tweeter
patent
1 patent
video
2 video uploaders

Citations

dimensions_citation
122 Dimensions

Readers on

mendeley
146 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
Published in
Cancer Chemotherapy & Pharmacology, May 2011
DOI 10.1007/s00280-011-1673-1
Pubmed ID
Authors

Masashi Kanai, Atsushi Imaizumi, Yoshihiko Otsuka, Hiroki Sasaki, Momo Hashiguchi, Kazu Tsujiko, Shigemi Matsumoto, Hiroshi Ishiguro, Tsutomu Chiba

Abstract

More and more preclinical studies support the idea that curcumin, a plant-derived natural polyphenol, could be a promising anticancer drug. However, poor bioavailability has limited its efficacy in clinical trials, and plasma curcumin levels remain low despite patients taking gram doses of curcumin.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Canada 1 <1%
Unknown 144 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 26 18%
Student > Master 25 17%
Researcher 21 14%
Student > Bachelor 14 10%
Other 11 8%
Other 33 23%
Unknown 16 11%
Readers by discipline Count As %
Medicine and Dentistry 35 24%
Agricultural and Biological Sciences 27 18%
Pharmacology, Toxicology and Pharmaceutical Science 16 11%
Biochemistry, Genetics and Molecular Biology 13 9%
Chemistry 10 7%
Other 22 15%
Unknown 23 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2019.
All research outputs
#1,355,271
of 15,020,327 outputs
Outputs from Cancer Chemotherapy & Pharmacology
#30
of 1,934 outputs
Outputs of similar age
#14,538
of 150,484 outputs
Outputs of similar age from Cancer Chemotherapy & Pharmacology
#2
of 26 outputs
Altmetric has tracked 15,020,327 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,934 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 150,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.